(Q39403721)

11 September 2017

Naloxone treatment for irritable bowel syndrome--a randomized controlled trial with an oral formulation (English)

1 reference

randomized controlled trial

11 September 2017

1 reference

Hawkes ND

1

1 reference

11 September 2017

Rhodes J

2

1 reference

11 September 2017

Evans BK

3

1 reference

11 September 2017

Rhodes P

4

1 reference

11 September 2017

Hawthorne AB

5

1 reference

11 September 2017

Thomas GA

6

1 reference

11 September 2017

language of work or name

English

0 references

publication date

1 September 2002

1 reference

Alimentary Pharmacology & Therapeutics

11 September 2017

1 reference

11 September 2017

16

1 reference

11 September 2017

9

1 reference

11 September 2017

1649-1654

1 reference

Impact of irritable bowel syndrome on quality of life and resource use in the United States and United Kingdom.

11 September 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Patient-perceived severity of irritable bowel syndrome in relation to symptoms, health resource utilization and quality of life.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Review article: an integrated approach to the irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Insights into opioid action in the intestinal tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Adequate relief as an endpoint in clinical trials in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Oral naloxone in opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Treatment of opioid-induced constipation with oral naloxone: A pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Oral naloxone reverses opioid-associated constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Oral methylnaltrexone for opioid-induced constipation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

Effect of an enteric-release formulation of naloxone on intestinal transit in volunteers taking codeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2002.01320.X

10.1046/J.1365-2036.2002.01320.X

21 January 2018

Identifiers

DOI

1 reference

11 September 2017

1 reference